

Special Issue

Angiogenesis

Message from the Guest Editors

Angiogenesis is the growth of blood vessels from the existing vasculature: metabolically active tissue is no more than a few hundred micrometers from a blood capillary, which is formed through the process of angiogenesis.

Angiogenesis occurs throughout life in both healthy subjects and subjects suffering from a disease; therefore, the control of angiogenesis has a therapeutic value and has been a field of significant interest during the past 40 years research.

One group of essential growth factor receptors in angiogenesis are vascular endothelial growth factor receptors (VEGFRs), a subfamily of receptor tyrosine kinases (RTKs). Multiple VEGF ligands with different preference and capability bind to VEGFRs and activate them in homo- and heterodimeric manners, representing a challenge for the study of their selective biochemical and cellular signaling in endothelial cell backgrounds and the role in leading angiogenesis processes.

This Special Issue welcomes original articles and reviews focused on the novelties in the angiogenesis field both in human health and disease.

Guest Editors

Dr. Angela Orecchia

Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy

Dr. Cristina M. Failla

Experimental Immunology Laboratory, IDI-IRCCS, Rome, Italy

Deadline for manuscript submissions

closed (31 October 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/163900

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).